In vitro anti-tumor immune response induced by dendritic cells transfected with recombinant adenovirus carrying mutant k-ras genes

Abstract

The specific anti-tumor immune response induced by mouse bone marrow dendritic cells (DCs) transfected with recombinant adenovirus carrying mutant k-ras genes was investigated. DCs were generated from mouse bone marrow in the presence of rmGM-CSF (3.3 ng/mL) and rmIL-4 (1.3 ng/mL) and detected by FACS, and then transfected with the recombinant adenovirus encoding mutant k-ras gene. The efficacy of transfection and T cell stimulating activity of DCs were detected. CTL activity of the mice vaccinated with DCs was observed. The results showed that DCs had dendritic veiled morphology. BmDCs highly expressed B7-1 (80%), B7-2 (77%), MHC II (70%), CD11c (65%), CD40 (70%) and CD54 (96%) with FACS, and no significant difference in the expression was observed before and after the transfection (P>0.05). The DCs transfected by mutant k-ras gene could significantly stimulate lymphocytes proliferation as compared with those transfected by Ad-c or non-modified DCs (P<0.05). DC vaccine transfected by mutant k-ras gene could induce CTL activity against Lewis lung cancer, but not against B16. The specific cytotoxicity against Lewis lung cancer in Ad-k-ras/12-transduced DC group was significantly higher than those in the control, vector and non-transfected DCs groups (P<0.05). It was concluded that special antitumor response could be induced by DCs transfected with recombinant adenovirus carrying mutant k-ras genes.

Keywords

adenovirus vector / mutant k-ras gene / dendritic cell / T lymphocyte

References

[1] AbramsS I, StanzialeS F, LuninS D, et al.. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses. Eur J Immunol., 1996, 26: 435-435

[2] Bergmann-LeitnerE S, KantorJ A, Lesley ShupertW, et al.. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele. Celluar Immunology, 1998, 187: 103-103

[3] BosJ L. ras oncogenes in human cancer: a review. Cancer Res, 1989, 49: 4682-4682

[4] RamakrishnaG, SithanandamG, ChengR Y, et al.. K-ras p21 expression and activity in lung and lung tumors. Exp Lung Res, 2000, 26: 659-659

[5] AbramsS I, DobrzanskiM J, WellsD T, et al.. Peptide-specific activation of cytolytic CD4 + T lymphocytes against tumor cells bearing mutated epitopes of K-ras p21. Eur J Immunol, 1995, 25: 2588-2588

[6] BanchereauJ, SteinmanR M. Dendritic cells and the control of immunity. Nature, 1998, 392: 245-245

[7] ZhaoF, ZhouQ H, QingY, et al.. Construction of mutant k-ras gene recombinant adenovirus. Chin J Lung Cancer (Chinese), 2002, 5(1): 14-14

[8] JacksonJ H, CochraneC G, BourneJ R, et al.. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Proc Natl Acad Sci U S A, 1990, 87: 3042-3042

[9] HeT C, ZhouS, CostaL T, et al.. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A, 1998, 95: 2509-2509

[10] InabaK, InabaM, RomaniN, et al.. Generation of large number of dendritic cells from mouse bone marrow cultures supplement with GM-CSF. J Exp Med, 1992, 176(6): 1693-1693

[11] HungerR E, BrandC U, StreitM, et al.. Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant. Exp Dermatol, 2001, 10(3): 161-161

[12] LinardB, BezieauS, BenlalamH, et al.. A ras-mutated peptide targeted by CTL infiltrating a human melanoma lesion. J Immunol, 2002, 168: 4802-4802

[13] ZhongL, Granelli-PipernoA, ChoiY, et al.. Recombinant adenovirus is an efficient and nonperturbing genetic vector for human dendritic cells. Eur J Immunol, 1999, 29: 964-964